Health
Ortho’s VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data – PRNewswire
/PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received…
RARITAN, N.J., March 23, 2021 /PRNewswire/ — Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2 Antigen Test, the first high-volume SARS-CoV-2 antigen assay to receive Emergency Use Authorization (EUA) in the United States.
“Communities and laboratories across the United States continue to seek fast, reliable,…
-
Business10 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General20 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Business14 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Noosa News13 hours agoShow your Anzac Spirit on the ‘Troop Train’